Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 51-56

  Wang, Jingbo ^a,b   Mahasittiwat, Pawinee ^a,e   Wong, Ka Kit ^c   Quint, Leslie E ^c   Kong, Feng Ming Spring ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CANCER HOSPITAL   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Veteran's Administration   (United States)

^e Mahidol University   (Thailand)

Author keywords

Disease progression; Doubling time; Non small cell lung cancer; Positron emission tomography computed tomography; Waiting time

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; GROSS TUMOR VOLUME; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TIME; TIME TO TREATMENT; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84866145530     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.06.010     Document Type: Article

References (26)

1. Mohammed N., Kestin L.L., Grills I.S., Battu M., Fitch D.L., Wong C.Y., et al. Rapid disease progression with delay in treatment of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 79:466-472.
2. Schultz E.M., Sanders G.D., Trotter P.R., Patz E.F., Silvestri G.A., Owens D.K., et al. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. Thorax 2008, 63:335-341.
3. Friberg S., Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 1997, 65:284-297.
4. Usuda K., Saito Y., Sagawa M., Sato M., Kanma K., Takahashi S., et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994, 74:2239-2244.
5. Yankelevitz D.F., Kostis W.J., Henschke C.I., Heelan R.T., Libby D.M., Pasmantier M.W., et al. Overdiagnosis in chest radiographic screening for lung carcinoma: frequency. Cancer 2003, 97:1271-1275.
6. Lindell R.M., Hartman T.E., Swensen S.J., Jett J.R., Midthun D.E., Tazelaar H.D., et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology 2007, 242:555-562.
7. Lindell R.M., Hartman T.E., Swensen S.J., Jett J.R., Midthun D.E., Mand rekar J.N. 5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest 2009, 136:1586-1595.
8. Jennings S.G., Winer-Muram H.T., Tann M., Ying J., Dowdeswell I. Distribution of stage I lung cancer growth rates determined with serial volumetric CT measurements. Radiology 2006, 241:554-563.
9. Kong F.M., Frey K., Quint L., Ten Haken R., Hayman J., Kessler M., et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007, 25:3116-3123.
10. Kong FM, Mahasittiwat P, Yuan S, Xie C, Ritter T, Shen Z, et al., Define tumor volume during radiotherapy to individulize adaptive radiation dose escalation in non-small cell lung cancer. In: ITART 2010 Imaging for Treatment Assessment in Radiation Therapy. June 21-22, 2010; National Harbor, MD.
11. Everitt S., Herschtal A., Callahan J., Plumridge N., Ball D., Kron T., et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer 2010, 116:5030-5037.
12. Tann M., Sandrasegaran K., Winer-Muram H.T., Jennings S.G., Welling M.E., Fletcher J.W. Can FDG-PET be used to predict growth of stage I lung cancer?. Clin Radiol 2008, 63:856-863.
13. Quint L.E., Cheng J., Schipper M., Chang A.C., Kalemkerian G. Lung lesion doubling times: values and variability based on method of volume determination. Clin Radiol 2008, 63:41-48.
14. Detterbeck F.C., Gibson C.J. Turning gray: the natural history of lung cancer over time. J Thorac Oncol 2008, 3:781-792.
15. Winer-Muram H.T., Jennings S.G., Tarver R.D., Aisen A.M., Tann M., Conces D.J., et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002, 223:798-805.
16. Vriens D., de Geus-Oei L.F., van Laarhoven H.W., Timmer-Bonte J.N., Krabbe P.F., Visser E.P., et al. Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. Nucl Med Commun 2009, 30:550-557.
17. Feng M., Kong F.M., Gross M., Fernando S., Hayman J.A., Ten Haken R.K. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 2009, 73:1228-1234.
18. van Loon J., Grutters J.P., Wanders R., Boersma L., Dingemans A.M., Bootsma G., et al. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. Eur J Cancer 2010, 46:110-119.
19. Frings V., de Langen A.J., Smit E.F., van Velden F.H., Hoekstra O.S., van Tinteren H., et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med 2010, 51:1870-1877.
20. Eastham D.V., Weerasuriya D., Wakelee H., Quon A., Maxim P., Le Q., et al. Quantification of progression of non-small cell lung cancer in the interval between diagnosis and radiotherapy treatment planning PET scans. Int J Radiat Oncol Biol Phys 2007, 69:S520-S521.
21. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, Suppl. 50(1):122S-150S.
22. Mackillop W.J., Bates J.H., O'Sullivan B., Withers H.R. The effect of delay in treatment on local control by radiotherapy. Int J Radiat Oncol Biol Phys 1996, 34:243-250.
23. Wang L., Correa C.R., Hayman J.A., Zhao L., Cease K., Brenner D., et al. Time to treatment in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009, 74:790-795.
24. Robinson E., Mohilever J., Zidan J., Sapir D. Delay in diagnosis of cancer. Possible effects on the stage of disease and survival. Cancer 1984, 54:1454-1460.
25. Chen Z., King W., Pearcey R., Kerba M., Mackillop W.J. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008, 87:3-16.
26. Williams M.V., Drinkwater K.J., Jones A., O'Sullivan B., Tait D. Waiting times for systemic cancer therapy in the United Kingdom in 2006. Br J Cancer 2008, 99:695-703.